🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

REGISTRATION IS OPEN FOR #ESHMM2026 March 26-28, 2026 / Stockholm, Sweden 8th Translational Research Conference Multiple Myeloma Chairs : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch, MD, PhD To register & for more information 👉bit.ly/4cy6PCW #ESHCONFERENCES #MMsm #HAEMATOLOGY

Our new paper out now in Blood Reviews, on a potentially groundbreaking therapy for AL Amyloidosis, CAEL-101 sciencedirect.com/science/articl…

Management of Al amyloidosis by Dr S. Lentzsch at the ⁦COMy⁩ ⁦IACH⁩

#COMy2025 | We just interviewed the lovely Meral Beksac (Meral Beksac) to hear her insights into the treatment of extra-medullary plasmacytoma, unmet needs in the highly heterogeneous disease of #MultipleMyeloma, & more! We'll soon be sharing this conversation on

⁦COMy⁩ is all about collaboration within the myeloma community and the ongoing pursuit of a cure for all. Honored to be here and to work with giants in the field like ⁦Suzanne Lentzsch, MD, PhD⁩ and Katja Weisel. Loved the all German effort ☺️. #mmsm

Elegant real-world study from Mayo Myeloma group showing that peak ALC >3K post-CAR infusion ➡️predictive biomarker for delayed neurotoxicity, enterocolitis, and CN palsy!! Simple, cheap, and scalable biomarker for designing interventions for primary prophylaxis targeting these

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint ir.prothena.com/investors/pres…

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. Plasma Cell Pete Noopur Raje Tom Martin Yi Lin Deepu Madduri

Anti-amyloid mAb in the context of Dara co-therapy may be set for up failure as binding to monocyte-FcR is competing with Dara and reducing ADP

This is just the beginning of the movement towards A.I. powered keyboard liberation for clinicians gift link wsj.com/health/healthc…

‼️#ASCO25 simultaneous publication by Ailawadhi et al:  Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. Read more: brnw.ch/21wT7Gq #MMSM

#ASCO25 Tuesday myeloma session. As nicely summarized by Suzanne Lentzsch, MD, PhD studies presented this morning re-emphasize that anti-CD38 quads should be the new SoC in NDMM, whether transplant eligible or not. Quads led to higher sustained MRD negativity rates & outcome even in HR #mmsm

To hear Suzanne Lentzsch, MD, PhD and myself on a related topic (high-risk #MYELOMA) in our recent Journal of Clinical Oncology Editorial Fellow podcast: music.youtube.com/watch?v=iHockd… Herbert Irving Comprehensive Cancer Center

Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by Suzanne Lentzsch, MD, PhD! #ASCO25 #MYELOMA #MRD Herbert Irving Comprehensive Cancer Center

Exciting results presented at #ASCO25 Tuesday myeloma session on JNJ-5322 BCMAxGPRC5DxCD3 trispecific showing ORR comparable to CART #mmsm

#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. Simultaneous JCO pub, highlighted NY Times ascopubs.org/doi/10.1200/JC… nytimes.com/2025/06/03/hea…

Fantastic results! Also today in the The New York Times Plasma Cell Pete Jordan Schecter, MD nytimes.com/2025/06/03/hea…

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

#Myeloma Paper of the Day: Retrospective study of AL #amyloidosis pts (n=130) w/ liver involvement finds median time to hepatic response (HepR) 21.5 mos; baseline ALP ≥4xULN predicted HepR; HemR, kappa isotype & front-line ASCT also predicted HepR: pubmed.ncbi.nlm.nih.gov/40509545/. #mmsm